Biogen Idec’s New R&D Boss, Doug Williams, Spurns Corner Office For A Return To Big Science

Biogen Idec appoints a veteran biotech scientist/businessman to lead its newly restructured R&D efforts, which will focus on therapeutics for neurology and immunology. This appointment comes on the heels of a series of recent licensing agreements between Biogen and Neurimmune (http://www.bloomberg.com/news/2010-12-20/biogen-idec-licenses-neurimmune-nerve-disorder-drugs-update1-.html), Amorfix (http://www.news-medical.net/news/20100715/Amorfix-grants-Biogen-Idec-exclusive-worldwide-rights-to-lead-ALS-monoclonal-antibodies.aspx) and Knopp (http://www.news-medical.net/news/20100818/Biogen-Idec-Knopp-Neurosciences-enter-license-agreement-for-KNS-760704-ALS-drug-candidate.aspx) for the development of promising ALS therapeutics.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail